MedPath

Study to assess Mirena user continuation and satisfaction for Contraception In InDian Subjects

Phase 4
Completed
Conditions
Health Condition 1: null- Contraception
Registration Number
CTRI/2014/02/004438
Lead Sponsor
Bayer Zydus Pharma Private Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
600
Inclusion Criteria

· Subject aged between 18-49 years who are initiating LNG IUS

therapy for contraception

· Subject willing to provide informed consent and comply with study

procedure

Exclusion Criteria

· Exclusion criteria must be read in conjunction with the local product

information.

The decision to initiate use of a LNG IUS for contraception is made

independently by the participant and her health care provider and is

not mandated by study design or protocol.

Study & Design

Study Type
PMS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath